You are using an outdated browser. Please upgrade your browser to improve your experience.

Tbio
UBE2L3
Ubiquitin-conjugating enzyme E2 L3

Protein Summary
Description
Ubiquitin-conjugating enzyme E2 that specifically acts with HECT-type and RBR family E3 ubiquitin-protein ligases. Does not function with most RING-containing E3 ubiquitin-protein ligases because it lacks intrinsic E3-independent reactivity with lysine: in contrast, it has activity with the RBR family E3 enzymes, such as PRKN and ARIH1, that function like function like RING-HECT hybrids. Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-11'-linked polyubiquitination. Involved in the selective degradation of short-lived and abnormal proteins. Down-regulated during the S-phase it is involved in progression through the cell cycle. Regulates nuclear hormone receptors transcriptional activity. May play a role in myelopoiesis. The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes ...more
Uniprot Accession IDs
Gene Name
Ensembl ID
  • ENST00000342192
  • ENSP00000344259
  • ENSG00000185651
  • ENST00000458578
  • ENSP00000400906
  • ENST00000545681
  • ENSP00000445931

Symbol
  • UBCE7
  • UBCH7
  • E2-F1
  • L-UBC
  • UBCH7
  • UbcM4
Illumination Graph
Knowledge Table
Most Knowledge About
Knowledge Value (0 to 1 scale)
disease perturbation
1
molecular function
1
virus perturbation
1
co-expressed gene
0.99
kinase perturbation
0.98


Protein Classes
IDG Development Level Summary
Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 69.44   (req: < 5)
Gene RIFs: 28   (req: <= 3)
Antibodies: 419   (req: <= 50)
Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 69.44   (req: >= 5)
Gene RIFs: 28   (req: > 3)
Antibodies: 419   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 21
Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0
Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0